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Abstract  
Oxidative stress is responsible for microvascular complications (hypertension, nephropathy, 
retinopathy, peripheral neuropathy) of diabetes, which during pregnancy increase both maternal and 
fetal complications. Chronic hypoxia and hyperglycemia result in increased oxidative stress and 
decreased antioxidant enzyme activity. However, oxidative stress induces also anti-oxidative 
reactions both in pregnant diabetes patients and in their fetuses. Not all type 1 diabetes patients with 
long-lasting disease develop microvascular complications, which suggests that some of these 
patients have protective mechanisms against these complications. Fetal erythropoietin (EPO) is the 
main regulator of red cell production in the mother and in the fetus, but it has also protective effects 
in various maternal and fetal tissues. This dual effect of EPO is based on EPO receptor (EPO-R) 
isoforms, which differ structurally and functionally from the hematopoietic EPO-R isoform. The 
tissue protective effects of EPO are based on its anti-apoptotic, anti-oxidative, anti-inflammatory, 
cell proliferative and angiogenic properties. Recent experimental and clinical studies have shown 
that EPO has also positive metabolic effects on hyperglycemia and diabetes, although these have 
not yet been fully delineated.  Whether the tissue protective and metabolic effects of EPO could 
have clinical benefits, are important topics for future research in diabetic pregnancies.      
 
Introduction 
Diabetes during pregnancy increases complications in the mother, the fetus and the newborn infant. 
Pregnancies in women with type 1 or type 2 diabetes have the most frequent and serious 
complications, but similar complications, although less frequent and less serious, occur also in 
women with gestational diabetes. Typical maternal complications in diabetic pregnancies are 
preeclampsia, gestational hypertension and preterm birth while congenital malformations (MF), 
intrauterine hypoxia, stillbirth and abnormal growth are common fetal complications. It is not quite 
clear whether these complications have a common background in diabetic pregnancies. In this 
review we discuss the possible roles of chronic hypoxia and oxidative stress in the pathogenesis of 
maternal and fetal complications in diabetic pregnancies. 
 
Oxidative stress in diabetic pregnancy 
Perinatal morbidities and mortality in type 1 diabetic pregnancies have remained relatively 
unchanged over the past 20 years. This bears out the fact that the precise mechanisms that cause the 
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type 1 diabetes related conditions have not yet been clearly established nor taken into account in the 
clinical practice [1]. Nevertheless, the influence of the oxidative stress, understood as an imbalance 
in the redox steady states, have proved to be a determining factor in type 1 diabetes related 
metabolic pathways. Hyperglycemia results in increased production of reactive oxygen species 
(ROS) through different abnormal metabolic pathways [2]. The most common ROS in human 
biology consist of superoxide free radicals, hydrogen peroxide, singlet oxygen, nitric oxide and 
proxy nitrite. While on the one hand both chronic hypoxia and high glucose levels result in 
increased oxidative stress, on the other hand it decreases antioxidant enzyme activity and impairs 
the endogenous antioxidant defense system [3]. This triggers a range of reactive molecules that can 
produce cellular damage by free radicals and includes lipid peroxidation and nitration, protein-thiol 
depletion, nucleic acid hydroxylation and nitration, DNA strand breakage and DNA adduct 
formation [4] and formation of ROS [5,6]. Furthermore, hyperglycemia causes an overproduction of 
advanced glycation end-products (AGE) and activates hexosamine biosynthesis [7]. Oxidant 
overproduction can ensue from either enhanced engagement of Nicotinamide adenine dinucleotide 
phosphate (NAPH) oxidase through an Angiotensin II type 1 receptor (AT1R)-mediated event or 
excessive mitochondrial oxidant production due to an energy surplus [8]. Consequently, both NAD 
synthesis and rebuilding of glutathione (GSH) by GSH reductase are reduced. The oxidants can be 
activated, at least in part, through various metabolic pathways such as polyol pathway, protein 
kinase C pathway and  p38-MAPK pathway and other stress-activate kinases dependent mechanism 
(including JUNK, GSK-3β and potentially IKK-β) [9–11]. Finally under a pro-oxidant status, a 
series of redox-sensitive transcription factors such as fetal NFκB, activator protein-1 (AP-1), HIF-
1α and insulin signaling factors that regulate GLUT-4 translocation become activated ultimately 
reducing the capacity for insulin-dependent glucose transport activity [12]. 
Erythropoietin (EPO), in addition to its regulation of erythropoiesis, has also anti-oxidative 
properties by acting anti-apoptotic and by being a potent scavenger of the hydroxyl, 2,2-diphenyl-1-
picrylhydrazyl and peroxyl radicals [13]. EPO also stimulates vasculogenesis by increasing the 
number of endothelial cells [13]. Angiogenesis is stimulated by low oxygen tissue content and 
regulates expression of EPO, vascular endothelial growth factor (VEGF), placental growth factor 
(PGF), and angiopoietins 1 and 2 [14].  Prolonged hypoxia is known to be the major stimulus of 
EPO production in the fetus [15]. In a study by Escobar et al, biomarkers of oxidative and 
nitrosative stress in amniotic fluid (AF) clearly correlated with AF concentration of EPO in type 1 
diabetic or insulin-treated gestational diabetes pregnant women [16]. Since EPO is not stored and 
does not cross the placenta, elevated concentration of EPO in fetal plasma and AF reflect EPO 
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synthesis and elimination, and significantly correlate with the intensity and duration of hypoxia 
[15,17]. Hence, under maternal metabolic stress fetuses experience  prolonged hypoxia with the 
subsequent inherent risks [18]. 
 
Metabolic roles of erythropoietin  
In addition to the regulation of erythropoiesis and its tissue protective properties [19], EPO effects 
also glucose metabolism. EPO decreases blood glucose levels both in non-diabetic human subjects 
and in rodents with diabetes [20,21]. Recombinant human EPO (rHuEPO) prevents diabetes in mice 
by promoting anti-apoptosis, anti-inflammation, cell proliferation and angiogenesis in pancreatic β-
cells [22,23]. EPO-receptors (EPO-R) are present both in human and rat pancreatic islets [24], 
which suggests that EPO can protect β-cells from apoptosis and possibly even prevent diabetes [25]. 
Experimental studies in rodents have shown that EPO reduces insulin resistance via regulation of 
EPO-R-mediated signaling pathways [20,26]. EPO-R in proopiomelanocortin (POMC) neurons in 
the hypothalamus regulate food intake and energy expenditure both in rodents and in humans 
[22,27]. During hypoxia glucose metabolism is regulated via POMC neurons [28]. EPO-Rs are 
highly expressed in these neurons, which suggests that EPO has several favorable effects on 
hyperglycemia [22,27]. EPO also decreases inflammation in white adipose tissue in animal models 
and normalizes insulin sensitivity in humans [22].  
 
Maternal complications  
The pathogenesis of diabetic microvascular complications is extremely complicated involving 
several different pathways resulting in oxidative stress and ROS formation [2]. Hypertension, 
diabetic nephropathy and/or retinopathy are especially important complications in pregnant diabetic 
women, because of potential serious complications to the fetus and the newborn infant. 
 
Diabetic hypertension 
Maternal and fetal endothelial dysfunction have been evidenced in type 1 and in type 2 diabetes, 
and also in gestational diabetes [29,30]. One of the most common disorders associated with 
hypertensive state during pregnancy is preeclampsia responsible for severe perinatal morbidity. The 
production of various mediators implying the cardiovascular and renal systems such as 
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inflammatory factors (e.g. TNF-α, IL-6), AT1R and ROS perturb the vascular homeostasis and 
mediate endothelial dysfunction in pregnant women [31]. Furthermore, nitrosative stress increase 
nitration of proteins in pregnant women with gestational diabetes, leading to endothelial and 
vascular dysfunction both in placental vessels and in the umbilical vasculature [32]. These changes 
together with maternal metabolic alterations in glucose, fatty acid, amino acid and placental ion 
transport mechanisms contribute to enhancing fetal hypoxia and acidosis and may lead the fetus into 
a catabolic state with deleterious postnatal consequences. 
 
Diabetic nephropathy 
Hyperglycemia, duration of diabetes and hypertension are risk factors for diabetic nephropathy. 
Several studies have shown that improvement of glucose control will decrease the development of 
diabetic nephropathy [33,34] but presently there are no known methods that could cure or prevent 
diabetic nephropathy. Both experimental and human studies suggest that hyperglycemia and renal 
hypoxia are the leading causes of diabetic nephropathy [35]. Mechanisms by which hyperglycemia 
can cause renal damage have recently been described [36]. Briefly, hyperglycemia can cause 
activation of vasoactive, inflammatory and fibrotic cytokines, increase formation of ROS and AGE, 
which all can decrease renal function, cause renal structural damage and finally lead to end-stage 
renal disease.  
Antioxidants prevent or ameliorate hyperglycemic unfavorable effects in the kidneys and vascular 
endothelium in experimental diabetes [37,38]. Interestingly, not all diabetics with a long-lasting 
duration of the disease develop microvascular complications [39]. The Joslin Medalist Study has 
revealed that occurrence of diabetic nephropathy or retinopathy did not correlate with glycemic 
control in some diabetic patients over a long period of time in contrast to the majority of diabetics 
with a much shorter duration of the disease [40]. This suggests that some of the type 1 diabetics 
have protective mechanisms against development of diabetic nephropathy [36].  Both in vitro and in 
vivo experimental studies have shown that high glucose results in ROS generation in renal tubular 
cells and that EPO can prevent this ROS generation [41]. A more recent study has shown that 
exogenous EPO has protective renal effects in type 2 diabetes mellitus patients with diabetic 
nephropathy [42]. However, the authors of a recent meta-analysis concluded that exogenous EPO or 
other erythropoiesis stimulating agents did not delay the progression of nephropathy [43]. 
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Diabetic retinopathy 
Hypoxia induces EPO expression in the retina [44] and exogenous EPO administration protects 
retinal neurons from acute ischemia-reperfusion injury [45]. High concentration of EPO has been 
observed in the vitreous fluid of patients with diabetic retinopathy [46]. This has led to controversy 
whether high levels of EPO in the eye of diabetes patients with proliferative retinopathy is a 
pathogenic cause of diabetic retinopathy [47] or whether these high levels of EPO is a 
compensatory neuroprotective mechanism of the retina [48]. Importantly, both preclinical and 
clinical studies suggest that EPO may actually have beneficial effects on diabetic proliferative 
retinopathy [49].    
 
The placenta in diabetic pregnancies 
Previous studies have suggested that fetal complications in type 1 diabetic pregnancies are mainly a 
result of placental structural abnormalities and function [50,51]. However, a recent study using 
more sophisticated methods, found only minimal structural differences between placentas of type 1 
diabetic and healthy non-diabetic pregnancies [52]. Importantly, villous surface area, placental 
capillary surface area and villous membrane thickness were not altered in type 1 diabetic 
pregnancies. It is very unlikely that the increased frequency of fetal chronic hypoxia in diabetic 
pregnancies is caused by placental structural changes with the exception of fetal intrauterine growth 
restriction caused by diabetic nephropathy and/or hypertension. 
 
Fetal and neonatal complications  
Congenital malformations 
Congenital malformations are 3-4 times more frequent in type 1 diabetic pregnancies than in normal 
pregnancies [53,54]. Although poor glycemic control (high HbA1c levels) during the first trimester 
of pregnancy is associated with an increased risk of fetal MF [54], the exact pathogenetic 
mechanism of fetal MF is not well understood. Most likely the pathogenesis of fetal MF is 
multifactorial, including hyperglycemia, hypoxic and endoplasmic stress, which induce oxidative 
stress and increased production of ROS (for review see Eriksson and Wentzel 2015) [55]. 
 
Abnormal fetal growth  
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Fetal overgrowth is the most common fetal complication in type 1 diabetic pregnancies with high 
frequencies of birth weights over 2 SD-units above the mean of the background population [1,56]. 
Chronic fetal hyperinsulinemia in euglycemic Rhesus monkeys results in fetal overgrowth and 
organomegaly [57]. Fetal birth weight z-scores correlate directly with fetal insulin levels [58] and 
with fetal EPO levels [59], which indicates that fetal overgrowth is often associated with chronic 
fetal hypoxia. Small-for-gestational age fetuses occur less frequently in pregestational diabetic 
pregnancies compared with the general population, because relative birth weights are shifted to the 
right also among growth restricted fetuses [60]. However, amniotic fluid EPO levels correlate with 
birth weight z-score in a U-shaped fashion in type 1 diabetic pregnancies [59]. Amniotic fluid EPO 
correlates negatively with birth weight z-score below -0.6 SD-units, which implies that these 
newborn infants are actually growth restricted and at risk of chronic hypoxia.             
 
Perinatal mortality  
Perinatal mortality is presently 4-5 times higher in both type 1 and type 2 diabetic pregnancies than 
in the general populations [61,62]. Pregestational diabetes is an independent risk factor for late 
stillbirths [63]. Before fetal electronic surveillance methods were available, stillbirths increased 
linearly during the last weeks of type 1 diabetic pregnancies reaching 20% at 40 weeks of gestation 
[64]. It can be assumed that the basic factors for the tendency of increasing stillbirths towards the 
end of type 1 diabetic pregnancies, although poorly understood, have not disappeared.  
Approximately half of the stillbirths in  these pregnancies occur before 30 weeks of pregnancy [18]. 
These stillbirth fetuses are in most cases growth restricted due to maternal hypertension and/or 
diabetic nephropathy, which suggests placental insufficiency (decreased nutrients and oxygen to the 
fetus) as the etiologic factor. In contrast, after 35 weeks of gestation stillbirth fetuses are usually 
overgrowth, but unexpected stillbirths occur also among normal weight fetuses [18]. The etiology 
of late stillbirths in diabetic pregnancies is most likely chronic intrauterine hypoxia caused by fetal 
hyperglycemia and hyperinsulinemia as indicated by high amniotic fluid and fetal plasma EPO 
levels [59,65].      
 
Chronic fetal hypoxia 
Chronic hypoxia is associated with oxidative and nitrosative stress. The fetus can adapt to 
reductions in oxygen delivery without life-threatening damage but with reduced somatic growth 
[66]. Interestingly enough, fetal oxygen delivery is the same but the glucose transfer to the fetus is 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
decreased resulting in fetal hypoinsulinemia and increased fetal lactate levels [67]. Nonetheless, 
under these circumstances the fetus becomes increasingly hypoxic and acidotic due to the increased 
anaerobic metabolism of glucose, and the fetus can enter into a catabolic state with long-term 
postnatal consequences [68]. 
Hyperinsulinemia during constant glucose concentration increases glucose oxidation and a fall in 
the arterial oxygen content both in adult human and experimental fetal sheep studies [69,70]. 
Moreover, hyperinsulinemia in the fetal sheep increases blood flow to the carcass but decreases 
blood flow to the placenta, which further enhances fetal hypoxia [71]. Hyperglycemia in fetal sheep 
results also in increased oxygen consumption, in a decrease in arterial oxygen content and in an 
exponential increase in fetal EPO concentration [72]. A similar exponential increase in fetal EPO 
concentration at birth was observed in type 1 diabetes pregnancies when umbilical artery pO2 fell 
below 2.0 kPa [59].  
Increased fetal plasma and amniotic fluid levels of EPO are observed in approximately 14% of type 
1 diabetic pregnancies [59], which gives further evidence that fetal chronic hypoxia often 
complicates these pregnancies. There are multiple maternal and fetal factors that can cause alone or 
in combination fetal hypoxia, and ultimately fetal demise in diabetic pregnancies. High HbA1c 
concentration shifts the maternal oxyhemoglobin dissociation curve to the left, which hampers 
oxygen delivery to the fetus. During maternal ketoacidosis the oxygen delivery to the fetus is even 
further reduced, especially during the recovery period, explaining the high stillbirth rate during 
maternal ketoacidosis [73]. Ante- and intrapartum fetal heart rate changes, cord blood acidosis at 
birth and low Apgar scores, all associated with fetal hypoxia, occur more frequently in type 1 
diabetic pregnancies, especially in women with poor glycemic control, than in non-diabetic 
pregnancies [56,74–76]. It is possible that placental abruption is more common among diabetic 
pregnancies, at least in pregnancies with large-for-gestational fetuses [77]. 
The fetus adapts to chronic hypoxia by redistributing its cardiac output in order to maintain 
adequate blood flow to the brain and heart and by increasing its EPO synthesis in order to increase 
its red cell production and oxygen-carrying capacity of blood.  
Prolonged hypoxia triggers the activation of transcription factor HIFs in several fetal tissues. This 
master regulator of hypoxia response is a heterodimeric transcription factor comprising of HIF1α 
and HIF-1β subunits.  In the presence of oxygen, the enzyme prolyl hydroxylase modifies HIF1α in 
proline sites within two oxygen-dependent degradation domains. This modification in HIF1α 
facilitates the ubiquitination for its degradation by the proteasome [78]. Under conditions of 
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hypoxia, the enzyme proline hydroxylase is unable to modify HIF1α, which is translocated to the 
nucleus where it binds to the hypoxia response elements (HREs) in the regulatory region of a 
number of genes, and stimulates the transcription of the Vefg gene and Epo genes and other hypoxia 
response genes [79]. 
In addition to regulating erythropoiesis, EPO has tissue-protective properties and repairing effects 
[19,80]. The tissue-protective effect of EPO is a result of EPO-R isoforms, which differ structurally 
and functionally from the erythropoietic EPO-R isoform. EPO levels needed for tissue-protection 
are 100-1000 times greater than EPO levels needed for erythropoiesis [19]. Local EPO synthesis 
has also been shown to take place in the fetal brain [81], which is another adaptive fetal response 
against hypoxia. Exogenous rHuEPO crosses the blood-brain barrier in concentrations known to 
cause tissue protection in the fetal sheep [82]. In asphyxiated newborn infants high EPO levels in 
the cerebrospinal fluid correlate with simultaneously obtained neonatal plasma EPO levels [83]. 
Exponential increases in amniotic fluid EPO concentrations have been shown in pregnancies 
complicated by hypertension or type 1 diabetes [59,84]. Over 10,000 mU/ml EPO plasma 
concentrations have been measured in the cord blood at birth of asphyxiated newborn infants [84]. 
Although the exact reason for these high fetal EPO concentrations are unknown, we have 
hypothesized that the fetus increases its EPO synthesis during chronic hypoxia in order to protect its 
brain and other vital organs against deleterious effects of hypoxia [85]. 
 
Fetal iron deficiency 
Iron is mandatory to fetal metabolism, energy production, and brain function. Newborn infants of 
diabetic mothers have often low ferritin levels and abnormal iron distribution at birth as a result of 
chronic intrauterine hypoxia [86,87]. Iron stores in the liver, heart and brain are almost totally 
depleted in fetuses who die in utero after 35 weeks in diabetic pregnancies [88]. This indicates that 
fetal death has been preceded by a prolonged period of fetal hypoxia, which results in increased 
production of red cells, for which iron stores are preferentially used for hemoglobin synthesis. Fetal 
and neonatal iron deficiency has long-term negative effects on cognitive and behavioral scores later 
in life [86,89]. 
 
Necrotizing enterocolitis of the newborn infant 
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Fetal hypoxia and birth asphyxia are associated with gut injury, impaired intestinal motility and 
necrotizing enterocolitis (NEC), especially in the preterm newborn infant [90,91]. In neonatal rat 
models, exogeneous EPO stimulates vasculogenesis of microvascular endothelial intestine cells and 
protects intestinal cells from NEC [92,93]. The fetus swallows up to 700 ml of amniotic fluid each 
day towards the end of pregnancy [94], although the reason for this is not well understood. One 
possibility could be that EPO and other cytokines in the amniotic fluid could exert protective effects 
locally in the fetal and neonatal intestine and hence improve neonatal feeding tolerance and prevent 
NEC [85,95].  
 
Adolescent cognitive function after intrauterine exposure to diabetes  
Maternal pre-conceptional and gestational control of hyperglycemia have relevant implications on 
short- and long-term offspring neurodevelopment [96]. Brain maturation is characterized by a pre-
established sequence of complex biological processes that encompass from the early embryonic 
period to late adolescent and young adulthood [97]. However, there is a large number of potential 
adverse factors during pregnancy that may inevitably alter brain maturation pattern. Among others, 
maternal obesity [98], prenatal famine [99], maternal infections [100], or insulin dependent diabetes 
[89] have been associated in epidemiological studies with neurocognitive impairment. Moreover, 
hyperglycemic intrauterine environment, hypoglycemia or ketoacidosis may directly exert a 
harmful effect upon the fetal brain. Finally, negative conditions associated with diabetic pregnancy 
such as prematurity or preeclampsia, also put the fetus at high risk of severe complications [101]. 
Recent studies have shown that infants born to diabetic mothers exhibited significantly higher 
mortality, hospital admissions and use of medications to the age of 15 [102]. In addition, intellectual 
assessment scales for the outcomes such as composite intelligence, verbal and nonverbal 
intelligence, composite memory, reading and writing difficulties, and attendance to classes showed 
a significant lower scoring for normalized and standardized intelligence indices among offspring of 
diabetic mothers as compared with controls [97,103,104]. However, no correlation with mothers’ 
glycated hemoglobin was found suggesting that maternal diabetes despite being adequately 
controlled has a negative impact on the neurodevelopment of the offspring [96]. But it can also be 
argued that "adequately controlled" was not adequate enough to prevent intrauterine negative 
effects.    
The pathophysiological explanation of impaired cognitive functions has not been fully clarified. 
During fetal life, the predominant source of brain energy is glucose, which crosses the placenta by 
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facilitated diffusion [105].  Maternal diabetes is associated with continuous fluctuations of in utero 
blood glucose levels but also with disturbances in fatty acid metabolism with a decreased transfer of 
docosahexaenoic acid to the fetus [106]. Docosahexaenoic acid accumulates in the brain especially 
in the third trimester and is essential for neurogenesis, neurotransmission, and protection from 
oxidative stress. Reduced bioavailability of this key metabolite has been suggested as a putative 
mechanism for programming altered neurodevelopment [106,107]. In addition, induced oxidative 
stress by hyperglycemic environment causes damage to the blood-brain barrier contributing to the 
infiltration of macrophages and pro-inflammatory cytokines. Altogether, these processes cause 
neuroinflammation, brain damage and contribute to neuronal cell death and long-term brain 
dysfunction [108]. 
 
Conclusions 
Oxidative stress is the likely common etiologic factor of microvascular complications of diabetes. 
Both pregestational and gestational diabetes increase complications in the mother, the fetus and the 
newborn infant, which can have long-lasting negative effects in the offspring later in life. Maternal 
hyperglycemia results in fetal hyperglycemia, which leads together with fetal hypoxia to increased 
oxidative stress and decreased antioxidant activity. Oxidative stress induces also anti-oxidative 
reactions both in pregnant diabetes patients and their fetuses. In this review we discuss the possible 
roles of chronic hypoxia and oxidative stress in the pathogenesis of maternal and fetal 
complications in diabetic pregnancies. Fetal EPO, besides regulating hematopoiesis, has also fetal 
tissue protective effects, which are based on EPO's anti-apoptotic, anti-oxidative, anti-
inflammatory, cell proliferative and angiogenic properties. More recent studies have shown that 
EPO has also positive metabolic effects in diabetic patients and in non-diabetic individuals. 
Whether the tissue protective and metabolic effects of EPO could be used clinically to prevent or 
delay the occurrence of diabetic complications both in the mother and her offspring, are important 
topics for future research on diabetic pregnancies.            
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Legend to Figure: 
 
Microvascular complications of diabetes during pregnancy (hypertension, nephropathy, retinopathy, 
peripheral neuropathy) are associated with maternal complications (preeclampsia, gestational 
hypertension, preterm birth) as well as with fetal and neonatal complications (congenital 
malformations, intrauterine hypoxia, stillbirth, abnormal growth, impaired cognitive function later 
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in life).  Oxidative and nitrosative stress, hyperglycemia, hypoglycemia and chronic hypoxia can 
further modulate maternal and fetal complications during diabetic pregnancy. 
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Highligths 
 
• Maternal hyperglycemia and fetal hypoxia result in increased oxidative stress  
• Increased oxidative stress triggers cellular damage by free radicals in the fetus   
• Erythropoietin has both hematopoietic and tissue protective properties in the fetus 
• Studies have shown that erythropoietin has positive metabolic effects on diabetes 
• Weather erythropoietin has clinical benefits for the offspring needs more studies     
